# Aristea Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aristea-therapeutics

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.aristeatx.com
- Total disclosed funding: $24M
- Latest round: Series B (Aug 5, 2021)
- Investors on record: 4

## About

Aristea Therapeutics, Inc. is a biotechnology firm focusing on the development of innovative immunotherapy drugs targeting orphan diseases, aiming to transform treatment options for patients in need.Founded in 2018 in San Diego, US, Aristea Therapeutics, Inc. specializes in the development of immunotherapy solutions. The company has raised a total of USD 23.5 mn in funding, with its latest round being a Series B on August 5, 2021, led by Fidelity Investments, alongside Arena Pharmaceuticals, Inc., Tekla Capital Management, and returning investor Novo Holdings. James Mackay serves as both founder and CEO, with experience in the biotechnology sector.Aristea Therapeutics, Inc. specializes in developing a range of immunotherapy drugs aimed at treating orphan diseases. Their product focus is on novel therapies designed to address unmet medical needs, particularly within rare disease segments, ensuring enhanced treatment options for patients.The company generates revenue through strategic partnerships and funding. The recent Series B funding of USD 23.5 mn will facilitate the advancement of its clinical programs and support the development of its product pipeline, directed towards innovative treatments for orphan diseases.Following its Series B funding in August 2021, Aristea Therapeutics, Inc. plans to expedite the clinical development of its immunotherapy drugs. The company is targeting expansion into new markets, with specific focus on North America and Europe, by 2023. The funding will be utilized to support these initiatives, ensuring that they can meet the needs of patients with orphan diseases effectively.

## Funding rounds

- Series B, Aug 5, 2021, $24M — Novo Holdings, Tekla Capital Management, Fidelity Investments, Arena Pharmaceuticals, Inc.

## Investors

- Novo Holdings — Series B
- Tekla Capital Management (https://capitalatlas.ai/funds/tekla-capital-management) — Series B
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series B
- Arena Pharmaceuticals, Inc. — Series B